The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic Respiratory Failure

Persistent inability of the respiratory system to maintain adequate gas exchange resulting in chronic hypoxemia (PaO2 < 60 mmHg on room air at sea level — Type I) or hypercapnia (PaCO2 > 45 mmHg with concurrent hypoxemia — Type II hypercapnic respiratory failure); develops gradually over weeks to years and is typically associated with chronic lung disease (COPD most common, interstitial lung diseases, severe pulmonary hypertension, cystic fibrosis, bronchiectasis), neuromuscular diseases (ALS, muscular dystrophy, myasthenia gravis, post-polio syndrome, spinal cord injury), chest wall disorders (kyphoscoliosis, ankylosing spondylitis, obesity hypoventilation syndrome), and central nervous system disorders affecting respiratory drive; clinical features include progressive dyspnea, exercise limitation, fatigue, morning headaches (CO2 retention), peripheral cyanosis, plethora, peripheral edema (cor pulmonale), cognitive changes; management involves treatment of underlying disease, long-term oxygen therapy (LTOT) for chronic hypoxemia (PaO2 < 55 mmHg or 56-59 mmHg with cor pulmonale, polycythemia, or signs of chronic hypoxia), non-invasive ventilation (NIV) for hypercapnic respiratory failure (typically with bi-level positive airway pressure — BiPAP), and pulmonary rehabilitation programs.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Chronic Respiratory Failure?

Chronic respiratory failure represents the persistent inability of the respiratory system to maintain adequate gas exchange, resulting in chronic hypoxemia and/or hypercapnia despite optimal medical management. The condition develops gradually over weeks to years from progressive lung or extrapulmonary disease, distinguishing it from acute respiratory failure which develops rapidly over hours to days. Chronic respiratory failure represents the end-stage of many pulmonary and extrapulmonary diseases, contributing significantly to morbidity, mortality, and healthcare utilization.

Classification by gas exchange abnormality: 1) Type I (hypoxemic) respiratory failure — PaO2 < 60 mmHg on room air at sea level with normal or low PaCO2; pathophysiology involves V/Q mismatch (most common — COPD, asthma, ILD), diffusion impairment (advanced ILD, emphysema), shunt (pulmonary AVMs, atelectasis), or low inspired oxygen (high altitude); typical causes include severe COPD with predominant emphysema, idiopathic pulmonary fibrosis, sarcoidosis, severe pulmonary hypertension, post-pulmonary embolism chronic thromboembolic pulmonary hypertension; 2) Type II (hypercapnic) respiratory failure — PaCO2 > 45 mmHg with concurrent hypoxemia; pathophysiology involves alveolar hypoventilation due to: a) Decreased respiratory drive (CNS depression, central hypoventilation syndromes); b) Respiratory pump failure (neuromuscular weakness, chest wall disorders); c) Increased dead space (severe COPD, advanced ILD with airway obstruction, pulmonary embolism); d) Increased CO2 production (rare); typical causes include severe COPD with respiratory pump fatigue, ALS and other neuromuscular diseases, severe kyphoscoliosis, obesity hypoventilation syndrome.

Etiologies — pulmonary parenchymal diseases: 1) Chronic obstructive pulmonary disease (COPD) — most common cause globally, affects 65 million worldwide; risk factors include smoking (most important), occupational exposures, biomass fuel exposure, alpha-1 antitrypsin deficiency in young patients; pathophysiology includes airway remodeling, mucus hypersecretion, alveolar destruction (emphysema), V/Q mismatch progressing to alveolar hypoventilation; 2) Idiopathic pulmonary fibrosis (IPF) — progressive fibrotic ILD typically Type I respiratory failure, mean survival 3-5 years from diagnosis without antifibrotics; 3) Other ILDs — non-specific interstitial pneumonia, hypersensitivity pneumonitis, sarcoidosis, connective tissue disease-associated ILD, drug-induced ILD; 4) Cystic fibrosis — increasingly common cause due to improved survival, leads to bronchiectasis, recurrent infections, progressive respiratory failure; 5) Bronchiectasis — chronic dilatation of bronchi from various causes (post-infectious, immunodeficiency, primary ciliary dyskinesia, mounier-kuhn syndrome); 6) Severe persistent asthma — rarely causes chronic respiratory failure, more typical to have acute exacerbations; 7) Pulmonary vascular diseases — pulmonary arterial hypertension (idiopathic, connective tissue disease-associated, congenital heart disease, drug-induced — appetite suppressants, methamphetamines), chronic thromboembolic pulmonary hypertension (CTEPH).

Etiologies — neuromuscular and chest wall disorders: 1) Amyotrophic lateral sclerosis (ALS) — most common neuromuscular cause requiring NIV initiation; progressive motor neuron disease causing respiratory pump failure; NIV improves quality of life and survival 6-12 months; 2) Duchenne muscular dystrophy — childhood-onset, progressive weakness, respiratory failure typically begins by adolescence requiring NIV then tracheostomy; 3) Myasthenia gravis — fluctuating muscle weakness, can present as chronic respiratory failure; 4) Spinal cord injury — high cervical (C1-C4) injuries cause severe respiratory pump impairment requiring lifelong ventilation; 5) Post-polio syndrome — re-emergence of weakness decades after polio infection affecting respiratory muscles; 6) Guillain-Barré syndrome chronic inflammatory variant; 7) Charcot-Marie-Tooth and other peripheral neuropathies; 8) Phrenic nerve injury (post-cardiac surgery, idiopathic); 9) Diaphragmatic paralysis (unilateral or bilateral); 10) Kyphoscoliosis — abnormal spine curvature reducing chest wall compliance and lung volumes; severity correlates with respiratory failure risk (Cobb angle > 100 degrees); 11) Ankylosing spondylitis — fixed thoracic kyphosis, restrictive defect; 12) Post-thoracoplasty (historical TB treatment); 13) Obesity hypoventilation syndrome (OHS) — defined as obesity (BMI > 30) with daytime hypercapnia (PaCO2 > 45 mmHg) not explained by other causes; affects 0.4 percent of general population, 10-20 percent of obese patients; 14) Central hypoventilation — congenital central hypoventilation syndrome (CCHS, PHOX2B mutations), post-stroke, brainstem lesions, drug-induced (chronic opioid use).

Symptoms

Progressive dyspnea on exertion (most common, then dyspnea at rest)
Exercise limitation and decreased exercise tolerance
Chronic fatigue and weakness
Morning headaches (especially with CO2 retention)
Cyanosis of lips, fingertips (chronic)
Peripheral edema (cor pulmonale)
Hepatomegaly (right heart failure)
Jugular venous distension
Plethora (ruddy complexion from polycythemia)
Cognitive changes — confusion, memory problems, irritability
Sleep disturbances (sleep-disordered breathing component)
Daytime somnolence (especially OHS, neuromuscular)
Loss of weight (cachexia in COPD)
Difficulty concentrating
Depression
Increased respiratory effort (accessory muscle use)
Chronic cough with sputum
Wheezing or crackles on auscultation
Reduced chest expansion
Clubbing (chronic hypoxemia, ILD)
Visible kyphoscoliosis or chest wall deformity
Generalized muscle weakness (neuromuscular cause)
Symptoms suggestive of obstructive sleep apnea (snoring, witnessed apnea)

Risk Factors

Smoking (most important risk for COPD)
Occupational exposures (silica, asbestos, coal dust, biological dusts, chemicals)
Biomass fuel exposure (cooking, heating)
Alpha-1 antitrypsin deficiency
Family history of lung disease or pulmonary hypertension
Severe asthma or chronic respiratory disease
Recurrent severe respiratory infections
Connective tissue disease (scleroderma, RA)
Inflammatory bowel disease (lung manifestations)
Immunosuppression (chronic infection risk)
Severe obesity (BMI > 35-40, OHS)
Sleep-disordered breathing (untreated OSA)
Neuromuscular disease (ALS, MD, MG)
Spinal cord injury
Post-polio history
Chest wall disorder (severe kyphoscoliosis, AS)
Phrenic nerve injury
Drug exposures (amiodarone, nitrofurantoin, methotrexate, anti-TNF, immune checkpoint inhibitors)
Radiation therapy to chest
Recurrent aspiration
Cardiovascular disease (left heart failure, PH)
Untreated obstructive sleep apnea
Chronic opioid use (central hypoventilation)
Older age (cumulative exposure)
Genetic factors (rare familial pulmonary fibrosis, BMPR2 mutations PAH)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Progressive shortness of breath
  • Decreased exercise tolerance
  • New onset dyspnea at rest
  • Cyanosis (blue lips, fingertips)
  • Morning headaches with respiratory disease
  • Edema in lower extremities
  • Fatigue with respiratory disease
  • Cognitive changes with respiratory disease
  • Daytime sleepiness with respiratory disease
  • Increasing oxygen requirement
  • Hospital admissions for respiratory failure
  • ICU admission for acute respiratory failure
  • New diagnosis of COPD with severe airflow limitation
  • Pulmonary fibrosis diagnosis
  • Neuromuscular disease with new respiratory symptoms
  • Severe obesity with sleep concerns
  • Pre-operative evaluation for major surgery in patients with respiratory disease
  • Pre-transplant evaluation
  • Disease progression monitoring
  • Treatment optimization (LTOT, NIV initiation)
  • Family or caregiver concerns about cognition or symptoms
  • Spinal cord injury with respiratory issues
  • Post-polio syndrome new symptoms
  • Failure of standard medical therapy

Treatment Methods

01
Initial assessment: comprehensive history (duration, progression, prior treatments, exposures including smoking and occupational, family history, medication history including amiodarone or other pulmonary toxic agents, comorbidities including cardiac and metabolic, sleep symptoms, neuromuscular symptoms, prior pulmonary infections), physical examination (vital signs including SpO2, respiratory rate, accessory muscle use, breath sounds, signs of cor pulmonale, edema, neuromuscular assessment, body habitus and BMI, kyphoscoliosis assessment), photographic documentation of clubbing, cyanosis
02
Diagnostic workup: 1) Arterial blood gas analysis (essential for diagnosis and classification — Type I PaO2 < 60 mmHg, Type II PaO2 < 60 mmHg + PaCO2 > 45 mmHg); 2) Pulmonary function tests including spirometry, lung volumes (TLC, RV), diffusion capacity (DLCO), maximal inspiratory and expiratory pressures (MIP/MEP for neuromuscular weakness assessment); 3) Pulse oximetry — overnight oximetry for nocturnal desaturation, exercise oximetry; 4) Chest imaging — chest X-ray initial, high-resolution CT for parenchymal disease evaluation, CT pulmonary angiography for vascular disease; 5) Echocardiography for cor pulmonale, pulmonary hypertension, left ventricular function; 6) Polysomnography if sleep-disordered breathing component suspected (OSA, hypoventilation, central apnea); 7) Specific tests — alpha-1 antitrypsin level (early-onset COPD), ANA and connective tissue disease panel (ILD), HIV testing (PCP risk), 6-minute walk test (functional assessment); 8) Cardiac evaluation — ECG, BNP for heart failure; 9) Right heart catheterization for pulmonary hypertension confirmation when severe; 10) Pulmonary rehabilitation assessment
03
Long-term oxygen therapy (LTOT): 1) Indications — chronic hypoxemia with PaO2 ≤ 55 mmHg or SpO2 ≤ 88 percent at rest on room air; OR PaO2 56-59 mmHg or SpO2 89 percent with one of: cor pulmonale, pulmonary hypertension, right heart failure, polycythemia (Hct > 55 percent), signs of chronic hypoxia; 2) Documented benefit in COPD (NOTT and MRC trials — improved survival 24/7 oxygen versus 12 hours); 3) Goals — maintain SpO2 > 90 percent at rest, exercise, and sleep; 4) Equipment options — concentrators (most common, electric, large stationary), portable concentrators, liquid oxygen systems, compressed gas cylinders; 5) Delivery devices — nasal cannula (most common), oxygen-conserving devices, transtracheal oxygen catheter (rarely), non-rebreather mask for higher requirements; 6) Patient education — proper use, fire safety (no smoking, distance from open flames), travel considerations (airline approval for portable concentrators), emergency planning; 7) Compliance challenges and strategies
04
Non-invasive ventilation (NIV): 1) Indications for chronic NIV — hypercapnic respiratory failure (PaCO2 ≥ 45 mmHg) in COPD, neuromuscular disease, chest wall disorders, OHS, central hypoventilation; 2) BiPAP (bi-level positive airway pressure) most commonly used — IPAP 12-20 cmH2O for inspiratory support, EPAP 4-8 cmH2O for expiratory positive pressure (helps maintain airway patency, reduces work of breathing); 3) Pressure adjustments based on tidal volume, comfort, blood gases; 4) Backup rate set for neuromuscular and central hypoventilation; 5) Mask interface — nasal masks, oronasal masks, full face masks; comfort and air leak management; 6) Acclimatization period — typically 2-4 weeks for adaptation; 7) Compliance support, follow-up, troubleshooting; 8) Documented survival and quality of life benefits in COPD with hypercapnia, neuromuscular diseases (ALS), OHS; 9) Volume-assured pressure support (AVAPS) for variable lung mechanics
05
Disease-specific treatments: 1) COPD — smoking cessation (most important), inhaled bronchodilators (LABA, LAMA, ICS for frequent exacerbations), pulmonary rehabilitation, vaccination (pneumococcal, influenza, COVID), exacerbation prevention, lung volume reduction surgery for selected emphysema, lung transplantation for end-stage; 2) Idiopathic pulmonary fibrosis — antifibrotic therapy (pirfenidone, nintedanib slowing decline), oxygen, pulmonary rehabilitation, lung transplantation; 3) Sarcoidosis — corticosteroids, immunosuppressants for progressive disease; 4) Pulmonary hypertension — pulmonary vasodilators based on classification (PDE5 inhibitors, endothelin receptor antagonists, prostacyclin analogs, soluble guanylate cyclase stimulators), oxygen, anticoagulation in PE-related; 5) Cystic fibrosis — CFTR modulators (Trikafta), airway clearance, antibiotics, mucolytics; 6) Neuromuscular diseases — disease-specific (riluzole and edaravone for ALS, immunotherapy for myasthenia, supportive for muscular dystrophy), respiratory muscle assessment and progression of NIV, eventual tracheostomy in some cases; 7) Obesity hypoventilation syndrome — weight loss (medical or surgical), CPAP for OSA component, BiPAP for hypoventilation; 8) Sleep-disordered breathing — CPAP for OSA, NIV for hypoventilation
06
Pulmonary rehabilitation: 1) Multidisciplinary program including exercise training, education, nutritional counseling, psychological support, smoking cessation; 2) Indications — chronic respiratory disease with persistent symptoms despite optimized medical therapy; 3) Components — aerobic endurance training (treadmill, cycle ergometer), strength training (resistance bands, weights), respiratory muscle training (incentive spirometer, threshold trainer), inspiratory muscle training (POWERbreathe); 4) Education on disease management, breathing techniques, energy conservation, medication use, oxygen use; 5) Nutritional assessment (cachexia in COPD, obesity in OHS); 6) Smoking cessation support; 7) Psychological support for depression and anxiety (common in chronic respiratory disease); 8) Documented benefits including improved exercise capacity, dyspnea, quality of life, exacerbation reduction; 9) Maintenance with long-term home exercise program
07
Management of comorbidities and complications: 1) Cardiovascular — left heart failure, atrial fibrillation, ischemic heart disease, treatment of pulmonary hypertension; 2) Cor pulmonale — diuretics, oxygen, treatment of underlying lung disease; 3) Polycythemia (Hct > 55 percent) — improvement with oxygen, occasional therapeutic phlebotomy if symptomatic; 4) Anemia — investigation and treatment of cause (chronic disease, iron deficiency, GI losses); 5) Osteoporosis — particularly in COPD, calcium, vitamin D, bisphosphonates; 6) Depression and anxiety — recognition and treatment; 7) Cachexia and malnutrition — nutritional support; 8) Recurrent infections — vaccination, prophylaxis when indicated, prompt treatment; 9) Pulmonary embolism (increased risk with chronic respiratory disease) — anticoagulation when indicated
08
End-of-life care and advance care planning: 1) Discussion of prognosis, treatment goals, advance directives early in chronic respiratory failure progression; 2) Tracheostomy and invasive ventilation considerations — particularly important for ALS patients (varies by patient choice and capacity); 3) Lung transplantation — referral for appropriate candidates (FEV1 < 25 percent in COPD, IPF with progressive decline, severe pulmonary hypertension); 4) Hospice and palliative care for advanced disease — symptom management (dyspnea — opioids judiciously, anxiolytics; secretions — atropine, glycopyrrolate; depression and anxiety); 5) Quality of life optimization throughout disease course; 6) Caregiver support (chronic disease management is exhausting for families); 7) Bereavement support post-mortem; 8) Documentation of preferences (DNR, no intubation, intensity of treatment limits)
09
Long-term outcomes and prognosis: prognosis depends on underlying disease, severity, response to treatment, comorbidities, age, and adherence; LTOT and NIV have demonstrated survival benefits in appropriate patients; pulmonary rehabilitation and disease-specific therapies improve quality of life and reduce hospitalizations; lung transplantation can be life-saving for advanced disease; integration of palliative care throughout disease course improves quality of life and may extend survival; multidisciplinary management with pulmonologist, primary care, specialty consultants (cardiology, sleep medicine, psychiatry, palliative care, pulmonary rehabilitation team) optimizes outcomes; ongoing research into novel therapies (antifibrotics, gene therapy for cystic fibrosis, advanced ventilatory support technologies, regenerative medicine)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.